FindTrial
Sign In

Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer

Phase I Alimta Combination With BMS-275183 (Oral Taxane)

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00103831
Enrollment
Unknown
Registered
2005-02-16
Start date
Unknown
Completion date
Unknown
Last updated
2010-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small Cell Lung Cancer

Keywords

NSCLC - non-small cell lung cancer

Brief summary

A phase I-II dose ranging study of BMS-275183 (oral taxane) in combination with pemetrexed (Alimta) in patients with recurrent Non-Small Cell Lung Cancer (NSCLC). The safety and efficacy of this combination will be studied.

Interventions

DRUGOral Taxane

Sponsors

Bristol-Myers Squibb
Lead SponsorINDUSTRY

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Advanced or metastatic pretreated NSCLC * Measurable disease * Adequate hematologic, hepatic and renal functions. * ECOG Performance Status 0-2

Exclusion criteria

* Inability to swallow capsules * Recent significant cardiovascular disease * Women who are pregnant or breastfeeding

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026